%0 Journal Article %1 Scheinberg2006 %A Scheinberg, Adam %A Hall, Kate %A Lam, Lawrence T %A O'Flaherty, Stephen %D 2006 %J J Paediatr Child Health %K Baclofen; Cerebral Palsy; Child; Child, Preschool; Double-Blind Method; Humans; Muscle Spasticity; New Zealand; Pilot Projects; Placebos %N 11 %P 715--720 %R 10.1111/j.1440-1754.2006.00957.x %T Oral baclofen in children with cerebral palsy: a double-blind cross-over pilot study. %U http://dx.doi.org/10.1111/j.1440-1754.2006.00957.x %V 42 %X AIM: To assess the effectiveness of oral baclofen in reducing spasticity and improving function in children with cerebral palsy. METHODS: A double-blind, randomised cross-over pilot study of oral baclofen versus placebo. Assessment tools included the Goal Attainment Scale, Pediatric Evaluation of Disability Inventory, Modified Tardieu Scale and parent questionnaire. RESULTS: Fifteen children with mean age 7.4 years (SD=2.7 years) and spastic or spastic/dystonic quadriplegia (Gross Motor Function Classification System Level IV or V) were enrolled. Children scored significantly better on the Goal Attainment Scale with baclofen compared with placebo (F(1,13)=4.5, P=0.05). There was no significant difference between baclofen and placebo for the Pediatric Evaluation of Disability Inventory or Modified Tardieu Scale. Parent questionnaire results are described. CONCLUSION: This pilot study demonstrates that oral baclofen has an effect beyond placebo in improving goal-oriented tasks, such as transfers, in children with spastic quadriplegic cerebral palsy.

@article{Scheinberg2006, abstract = {AIM: To assess the effectiveness of oral baclofen in reducing spasticity and improving function in children with cerebral palsy. METHODS: A double-blind, randomised cross-over pilot study of oral baclofen versus placebo. Assessment tools included the Goal Attainment Scale, Pediatric Evaluation of Disability Inventory, Modified Tardieu Scale and parent questionnaire. RESULTS: Fifteen children with mean age 7.4 years (SD=2.7 years) and spastic or spastic/dystonic quadriplegia (Gross Motor Function Classification System Level IV or V) were enrolled. Children scored significantly better on the Goal Attainment Scale with baclofen compared with placebo (F(1,13)=4.5, P=0.05). There was no significant difference between baclofen and placebo for the Pediatric Evaluation of Disability Inventory or Modified Tardieu Scale. Parent questionnaire results are described. CONCLUSION: This pilot study demonstrates that oral baclofen has an effect beyond placebo in improving goal-oriented tasks, such as transfers, in children with spastic quadriplegic cerebral palsy.}, added-at = {2014-07-19T21:14:31.000+0200}, author = {Scheinberg, Adam and Hall, Kate and Lam, Lawrence T and O'Flaherty, Stephen}, biburl = {https://www.bibsonomy.org/bibtex/2eac7d02d87e8f7106555bf4f3aa9a42a/ar0berts}, doi = {10.1111/j.1440-1754.2006.00957.x}, groups = {public}, interhash = {92e93de1e610f712551ea97a2750ada6}, intrahash = {eac7d02d87e8f7106555bf4f3aa9a42a}, journal = {J Paediatr Child Health}, keywords = {Baclofen; Cerebral Palsy; Child; Child, Preschool; Double-Blind Method; Humans; Muscle Spasticity; New Zealand; Pilot Projects; Placebos}, month = Nov, number = 11, pages = {715--720}, pii = {JPC957}, pmid = {17044900}, timestamp = {2014-07-19T21:14:31.000+0200}, title = {Oral baclofen in children with cerebral palsy: a double-blind cross-over pilot study.}, url = {http://dx.doi.org/10.1111/j.1440-1754.2006.00957.x}, username = {ar0berts}, volume = 42, year = 2006 }